Cargando…

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma

Although the successful clinical trials of immunotherapy show promising strategies for many cancers, its application in glioma has lagged in comparison with the progress seen in other cancers. Both isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletions are critical molecular alterations aff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wanzun, Qiu, Xianxin, Sun, Pian, Ye, Yuling, Huang, Qingting, Kong, Lin, Lu, Jiade J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167204/ https://www.ncbi.nlm.nih.gov/pubmed/34141867 http://dx.doi.org/10.1016/j.omto.2021.04.010

Ejemplares similares

Identification of molecular subtypes based on inflammatory response in lower-grade glioma
por: Lin, Wanzun, et al.
Publicado: (2022)

VMP1, a novel prognostic biomarker, contributes to glioma development by regulating autophagy
por: Lin, Wanzun, et al.
Publicado: (2021)

Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study
por: Qiu, Xianxin, et al.
Publicado: (2022)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma
por: Lin, Wanzun, et al.
Publicado: (2021)

Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups
por: Lin, Wanzun, et al.
Publicado: (2020)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

A three-lncRNA signature predicts clinical outcomes in low-grade glioma patients after radiotherapy
por: Lin, Wanzun, et al.
Publicado: (2020)

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation
por: Lin, Wanzun, et al.
Publicado: (2023)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma
por: Kang, Houyi, et al.
Publicado: (2020)

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
por: Persico, Pasquale, et al.
Publicado: (2022)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy
por: Qiu, Xianxin, et al.
Publicado: (2022)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images
por: Jiang, Shuai, et al.
Publicado: (2021)

Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients
por: Ren, Xiaohui, et al.
Publicado: (2012)

A Comparison Study of Machine Learning (Random Survival Forest) and Classic Statistic (Cox Proportional Hazards) for Predicting Progression in High-Grade Glioma after Proton and Carbon Ion Radiotherapy
por: Qiu, Xianxin, et al.
Publicado: (2020)

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma
por: Deng, Xiangyang, et al.
Publicado: (2019)

Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas
por: Zhang, Lu, et al.
Publicado: (2023)

ACT-5 Prognosis of IDH-mut lower-grade gliomas in Hokkaido University Hospital
por: Yamaguchi, Shigeru, et al.
Publicado: (2021)

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
por: Liu, Feng-Min, et al.
Publicado: (2021)

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period
por: Svenjeby, Caroline, et al.
Publicado: (2022)

Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022)

Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with IDH mutations and 1p/19q co-deletion
por: Zhao, Xin-Wei, et al.
Publicado: (2017)

GPGPS: a robust prognostic gene pair signature of glioma ensembling IDH mutation and 1p/19q co-deletion
por: Cheng, Lixin, et al.
Publicado: (2023)

Particle Beam Radiation Therapy for Adenoid Cystic Carcinoma of the Nasal Cavity and Paranasal Sinuses
por: Hu, Weixu, et al.
Publicado: (2020)

Particle beam radiation therapy for sinonasal malignancies: Single institutional experience at the Shanghai Proton and Heavy Ion Center
por: Hu, Weixu, et al.
Publicado: (2020)

Intensity-modulated proton and carbon-ion radiation therapy in the management of major salivary gland carcinomas
por: Huang, Qingting, et al.
Publicado: (2022)

Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies
por: Yang, Jing, et al.
Publicado: (2022)

Comparison of the efficacy and toxicity of postoperative proton versus carbon ion radiotherapy for head and neck cancers
por: Huang, Qingting, et al.
Publicado: (2022)

The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx
por: Hu, Jiyi, et al.
Publicado: (2022)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion
por: Huang, Shang-Pen, et al.
Publicado: (2019)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma
por: Wu, Chenxing, et al.
Publicado: (2020)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tj5l16ohrv3k8apat9dceurpfs